Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Central nervous system (CNS) leukemia is a poor prognostic factor for allogeneic
hematopoietic stem cell transplantation (allo-HSCT). Thiotepa can penetrate the blood-brain
barrier and has immunosuppressive effects and similar effects to irradiation in allo-HSCT.
This project aims to investigate whether the TBF regimen is superior to the traditional
modified BuCY2 regimen to improve the long-term survival of the CNS leukemia patients.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University